PA8426401A1 - Formula de liberacion prolongada - Google Patents
Formula de liberacion prolongadaInfo
- Publication number
- PA8426401A1 PA8426401A1 PA8426401A PA8426401A PA8426401A1 PA 8426401 A1 PA8426401 A1 PA 8426401A1 PA 8426401 A PA8426401 A PA 8426401A PA 8426401 A PA8426401 A PA 8426401A PA 8426401 A1 PA8426401 A1 PA 8426401A1
- Authority
- PA
- Panama
- Prior art keywords
- prolonged release
- release formula
- formula
- nause
- posological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL PRESENTE INVENTO SE RELACIONA CON UNA FORMULA POSOLOGICA Y DOSIS UNITARIA DE LA MISMA, DE CLORHIDRATO DE VENLAFAXINA, UN AGENTE ANTIDEPRESIVO, DE LIBERACION PROLONGADA SOBRE 24 HORAS, QUE OFRECE UN CONTROL DE LAS CONCENTRACIONES PLASMATICAS MEJOR QUE EL DE LAS FORMULAS CONVENCIONALES EN TABLETAS QUE DEBERAN ADMINISTRARSE DOS O MAS VECES AL DIA, Y QUE TAMBIEN SE ASOCIA CON UNA INCIDENCIA MAS BAJA DE NAUSEAS, Y VOMITOS QUE LAS TABLETAS CONVENCIONALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1400696P | 1996-03-25 | 1996-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8426401A1 true PA8426401A1 (es) | 2000-05-24 |
Family
ID=21762972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA8426401A PA8426401A1 (es) | 1996-03-25 | 1997-03-14 | Formula de liberacion prolongada |
Country Status (34)
Country | Link |
---|---|
EP (2) | EP0797991B1 (es) |
JP (2) | JP4771565B2 (es) |
KR (1) | KR101096512B1 (es) |
CN (2) | CN1090018C (es) |
AR (1) | AR006519A1 (es) |
AT (1) | ATE257011T1 (es) |
AU (1) | AU727653B2 (es) |
BR (1) | BR9701304A (es) |
CA (1) | CA2199778C (es) |
CO (1) | CO4761054A1 (es) |
CY (1) | CY2442B1 (es) |
CZ (1) | CZ291637B6 (es) |
DE (1) | DE69727000T2 (es) |
DK (1) | DK0797991T3 (es) |
EG (1) | EG24198A (es) |
ES (1) | ES2210454T3 (es) |
HK (1) | HK1056686A1 (es) |
HU (1) | HU224617B1 (es) |
IL (1) | IL120382A (es) |
IN (1) | IN187337B (es) |
NO (2) | NO320355B1 (es) |
NZ (1) | NZ314442A (es) |
PA (1) | PA8426401A1 (es) |
PE (1) | PE57198A1 (es) |
PL (2) | PL195564B1 (es) |
PT (1) | PT797991E (es) |
RU (1) | RU2176912C2 (es) |
SK (1) | SK281530B6 (es) |
SV (1) | SV1997000015A (es) |
TR (1) | TR199700190A2 (es) |
TW (1) | TW493993B (es) |
UA (1) | UA44904C2 (es) |
UY (1) | UY24613A1 (es) |
ZA (1) | ZA972403B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
JP3379461B2 (ja) * | 1998-08-06 | 2003-02-24 | 三菱電機株式会社 | コア部材の積層金型装置、コア部材の積層方法および電動機 |
EP1178780B1 (en) * | 1999-05-20 | 2007-07-18 | ELAN CORPORATION, Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
ES2162746B1 (es) * | 1999-10-21 | 2003-02-16 | Lipotec Sa | Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion. |
FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
SK5762003A3 (en) * | 2000-10-19 | 2003-11-04 | Teva Pharma | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
HUP0104872A3 (en) * | 2001-11-13 | 2004-04-28 | Egis Gyogyszergyar Nyilvanosan | New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use |
AU2003219117A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Extended release venlafaxine formulations |
AU2003226751A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Low water-soluble venlafaxine salts |
AU2003221535A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine besylate |
US20060246132A1 (en) * | 2003-02-07 | 2006-11-02 | Fjalar Johannsson | Sustained release formulations of venlafaxine |
TW200503670A (en) * | 2003-03-28 | 2005-02-01 | Sandoz Ag | Venlafaxine compositions |
DE60309565T3 (de) * | 2003-05-02 | 2015-01-15 | Dexcel Ltd. | Tablettenzubereitung mit verlängerter Freisetzung von Venlafaxin |
IN2003MU00504A (es) * | 2003-06-05 | 2005-05-13 | Alembic Ltd | |
CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
ES2271514T3 (es) | 2003-07-30 | 2007-04-16 | Pharmathen S.A. | Formulacion de liberacion sostenida para clorhidrato de venlafaxina. |
WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
HUP0303382A2 (hu) * | 2003-10-10 | 2005-08-29 | EGIS Gyógyszergyár Rt. | Venlafaxin-hidroklorid-tartalmú pelletek |
EP1523979A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release pharmaceutical dosage form |
EP1523981A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release formulations of venlafaxine |
DE10359154A1 (de) | 2003-12-16 | 2005-07-28 | Krka Tovarna Zdravil, D.D. | Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I |
DE602004006443T2 (de) | 2004-02-04 | 2008-01-10 | Alembic Ltd., Vadodara | Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US7776358B2 (en) | 2004-07-22 | 2010-08-17 | Synthon Ip Inc. | Extended release venlafaxine besylate tablets |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN100463676C (zh) * | 2004-11-11 | 2009-02-25 | 成都康弘药业集团股份有限公司 | 一种盐酸文拉法辛控释片制剂及其制备方法 |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
EP2007360B1 (en) * | 2006-04-03 | 2014-11-26 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
HUE029173T2 (hu) | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
KR100791194B1 (ko) * | 2006-06-12 | 2008-01-02 | 코오롱제약주식회사 | 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법 |
JP6045347B2 (ja) * | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
WO2011132008A2 (en) | 2010-04-22 | 2011-10-27 | EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság | Controlled release pharmaceutical composition |
WO2012104852A1 (en) | 2011-01-31 | 2012-08-09 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
CN103893151B (zh) * | 2012-12-31 | 2018-04-27 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸文拉法辛缓释胶囊及其制备方法 |
US12042566B2 (en) | 2017-05-17 | 2024-07-23 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
CN114288273B (zh) * | 2022-02-11 | 2022-10-18 | 桂林华信制药有限公司 | 一种盐酸文拉法辛缓释胶囊及其生产工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561204A (en) * | 1977-06-01 | 1980-02-13 | Ici Ltd | Sustained release pharmaceutical composition |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4761501A (en) * | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
DE69429895T2 (de) * | 1993-06-28 | 2002-08-29 | American Home Products Corp., Madison | Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
-
1997
- 1997-03-04 PE PE00015497A patent/PE57198A1/es not_active IP Right Cessation
- 1997-03-05 AR ARP970100883 patent/AR006519A1/es unknown
- 1997-03-06 IL IL12038297A patent/IL120382A/xx unknown
- 1997-03-07 TW TW86102797A patent/TW493993B/zh not_active IP Right Cessation
- 1997-03-07 SK SK301-97A patent/SK281530B6/sk not_active IP Right Cessation
- 1997-03-10 CO CO97012838A patent/CO4761054A1/es unknown
- 1997-03-10 SV SV1997000015A patent/SV1997000015A/es active IP Right Grant
- 1997-03-11 EG EG18297A patent/EG24198A/xx active
- 1997-03-12 UA UA97031116A patent/UA44904C2/uk unknown
- 1997-03-12 CA CA 2199778 patent/CA2199778C/en not_active Expired - Lifetime
- 1997-03-13 TR TR97/00190A patent/TR199700190A2/xx unknown
- 1997-03-13 CZ CZ1997772A patent/CZ291637B6/cs not_active IP Right Cessation
- 1997-03-13 PL PL368424A patent/PL195564B1/pl unknown
- 1997-03-13 RU RU97103563A patent/RU2176912C2/ru not_active IP Right Cessation
- 1997-03-13 PL PL97318954A patent/PL188444B1/pl unknown
- 1997-03-14 JP JP06078197A patent/JP4771565B2/ja not_active Expired - Fee Related
- 1997-03-14 NO NO19971206A patent/NO320355B1/no not_active IP Right Cessation
- 1997-03-14 HU HU9700589A patent/HU224617B1/hu not_active IP Right Cessation
- 1997-03-14 PA PA8426401A patent/PA8426401A1/es unknown
- 1997-03-14 BR BR9701304A patent/BR9701304A/pt not_active IP Right Cessation
- 1997-03-14 KR KR1019970008590A patent/KR101096512B1/ko active IP Right Grant
- 1997-03-14 CN CN97109594A patent/CN1090018C/zh not_active Expired - Lifetime
- 1997-03-19 NZ NZ31444297A patent/NZ314442A/xx not_active IP Right Cessation
- 1997-03-19 ZA ZA972403A patent/ZA972403B/xx unknown
- 1997-03-20 AU AU16400/97A patent/AU727653B2/en not_active Expired
- 1997-03-21 IN IN507CA1997 patent/IN187337B/en unknown
- 1997-03-21 DE DE1997627000 patent/DE69727000T2/de not_active Expired - Lifetime
- 1997-03-21 EP EP19970301937 patent/EP0797991B1/en not_active Expired - Lifetime
- 1997-03-21 ES ES97301937T patent/ES2210454T3/es not_active Expired - Lifetime
- 1997-03-21 EP EP14198408.8A patent/EP2881110A1/en not_active Withdrawn
- 1997-03-21 AT AT97301937T patent/ATE257011T1/de active
- 1997-03-21 PT PT97301937T patent/PT797991E/pt unknown
- 1997-03-21 DK DK97301937T patent/DK0797991T3/da active
- 1997-07-10 UY UY24613A patent/UY24613A1/es not_active IP Right Cessation
-
2001
- 2001-12-14 CN CN01143869A patent/CN1403077A/zh active Pending
-
2003
- 2003-12-12 HK HK03109076.5A patent/HK1056686A1/xx not_active IP Right Cessation
-
2004
- 2004-05-27 CY CY0400040A patent/CY2442B1/xx unknown
-
2005
- 2005-01-24 NO NO20050379A patent/NO20050379L/no not_active Application Discontinuation
-
2008
- 2008-03-13 JP JP2008064149A patent/JP2008156374A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8426401A1 (es) | Formula de liberacion prolongada | |
PA8462501A1 (es) | Formula de liberacion prolongada | |
ES2105338T3 (es) | Derivado de ciclohexanol, agente y composicion que contiene el mismo para impartir sensacion agradable de frio, procedimiento para la fabricacion del derivado e intermediario para su produccion. | |
ES2188177T3 (es) | Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina. | |
UY24354A1 (es) | Composiciones farmacéuticas que contienen epinastina | |
UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
MX9202328A (es) | Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo. | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
BR0311325A (pt) | Métodos e composições para aliviar a dor | |
ES2169147T3 (es) | Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento. | |
MX9307644A (es) | Medicamento que incluye 2-amino-6-n-propil-amino-4,5, 6, 7,-tetrahidrobenzotiazol con efecto antidepresivo. | |
BR9910024A (pt) | Agente contra resfriado | |
AR007852A1 (es) | Una composicion de barra de jabon de base anionica que comprende tensioactivos anfoteros y/o zwitterionicos | |
BR0314129A (pt) | Formulações de liberação modificadas de oxcarbazepina e derivados destas | |
FI962550A (fi) | Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa | |
ES2171669T3 (es) | Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion. | |
ES2305567T3 (es) | Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas. | |
AR016473A1 (es) | Preparado efervescente y procedimiento para su preparacion | |
MX9405371A (es) | Derivado de naftilo. | |
HUP9900504A2 (en) | Use of insect pheromones for producing pharmaceutical compositions having antiglucocorticoid effect | |
ID27755A (id) | Komposisi parfum | |
UY26748A1 (es) | Uso de una cepa de bacterias lácticas exógenas contra enfermadades relacionadas con actinomyces naeslundii | |
ECSP972046A (es) | Formula de liberacion prolongada | |
ES2122005T3 (es) | Medicamento que contiene (-)-metrifonato. | |
HN2001000119A (es) | S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares. |